DuPont's new nonnucleoside analog, efavirenz (Sustiva), is embroiled in a controversy related to the high costs of the drug. DuPont has offered a 5 percent discount off of the current ADAP price, but several large ADAP programs are not including efavirenz yet. The company has committed to providing the drug free of charge to financially-needy patients, but only as a last resort. Recently, a new protease inhibitor called amprenavir (Agenerase) has been introduced by Glaxo Wellcome. Amprenavir is available from an expanded access program for patients who have failed one protease inhibitor and who fit into one of three treatment protocols. Problems with ingesting the drug are reviewed. Glaxo expects FDA approval for amprenavir in the near future.